AKAhmed Kotb

Ahmed Kotb

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Ahmed Kotb has a total of 17 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Procedural outcomes of laparoscopic caudate lobe resection: A systematic review and meta-analysis

    by Ahmed Kotb, Louis Evans, Emily Sams, Andrew Naguib, Shahin Hajibandeh, Thomas Satyadas

    Shahab Hajibandeh, Ahmed Kotb, Louis Evans, Emily Sams, Andrew Naguib, Shahin Hajibandeh, Thomas Satyadas. Ann Hepatobiliary Pancreat Surg 2023;27:6-19. https://doi.org/10.14701/ahbps.22-045


  • Cumulative incidence rates for CNS and non-CNS progression by baseline CNS metastases status using data from two alectinib phase II studies.

    by Shirish M. Gadgeel, Alice Tsang Shaw, Fabrice Barlesi, Lucio Crino, James Chih-Hsin Yang, Anne-Marie C. Dingemans, Dong-Wan Kim, Filippo De Marinis, Mathias Schulz, Shiyao Liu, et al.

    9063 Background: Alectinib showed robust efficacy and safety in two phase II studies (NP28673 [NCT01801111] and NP28761 [NCT01871805]) of patients (pts) with previously treated ALK+ NSCLC. A pooled analysis of these studies also showed highly consistent efficacy of alectinib in the central nervous system (CNS) (Gadgeel et al, WCLC 2015). This exploratory analysis used these pooled data to evaluate the cumulative incidence rate (CIR) of CNS and non-CNS progression for pts with and without CNS metastases (mets) at baseline (BL). Methods: All pts (n = 225) were ≥ 18 years with confirmed ALK+ NSCLC, which had progressed after prior crizotinib. They received 600 mg oral alectinib twice daily. All patients had BL imaging to detect CNS mets, with further prospective imaging as per the protocols. In this analysis, response was determined by RECIST v1.1, and progression (PD) categorized as CNS or non-CNS. CIR was calculated using competing risks methodology. Results: BL characteristics were similar in pts with (n = 136) or without (n = 89) BL CNS mets. Median follow-up was 12.8 months. CIRs at 6, 12 and 18 months are shown in the Table. In the BL CNS mets group, pts with prior radiation (RT; n = 95) had a slightly more rapid rate of CNS PD (39.7% [29.6–49.8] at 12 months) than those with no prior RT (n = 41; 20.1% [7.6–32.6] at 12 months) (p < 0.05), perhaps due to, for e.g., greater disease burden. Conclusions: These pooled phase II study data suggest that alectinib is effective in pts with BL CNS mets, regardless of prior RT. Based on the low incidence of CNS PD in pts without CNS mets at BL, alectinib may also have a potential preventative effect in these pts. The ongoing phase III ALEX study will assess rate of CNS relapse in pts receiving first-line alectinib vs crizotinib. Clinical trial information: NCT01801111 and NCT01871805.